Shares of Calithera Biosciences Inc (NASDAQ:CALA) have received a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $14.40.
A number of equities research analysts recently commented on the company. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Thursday. ValuEngine lowered Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Monday, November 6th. Finally, William Blair assumed coverage on Calithera Biosciences in a research report on Thursday, October 5th. They set an “outperform” rating on the stock.
Shares of Calithera Biosciences (NASDAQ:CALA) traded up $0.05 on Friday, hitting $8.40. The stock had a trading volume of 313,206 shares, compared to its average volume of 364,800. Calithera Biosciences has a fifty-two week low of $4.10 and a fifty-two week high of $20.05. The firm has a market cap of $298.00, a PE ratio of -8.48 and a beta of 2.87.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. boosted its position in Calithera Biosciences by 249.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 71,600 shares of the biotechnology company’s stock valued at $1,064,000 after buying an additional 51,100 shares during the last quarter. Rhumbline Advisers bought a new position in Calithera Biosciences in the 2nd quarter valued at $503,000. Bank of New York Mellon Corp boosted its position in Calithera Biosciences by 230.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 108,102 shares of the biotechnology company’s stock valued at $1,605,000 after buying an additional 75,414 shares during the last quarter. Legal & General Group Plc bought a new position in Calithera Biosciences in the 2nd quarter valued at $120,000. Finally, Wells Fargo & Company MN boosted its position in Calithera Biosciences by 705.3% in the 2nd quarter. Wells Fargo & Company MN now owns 26,832 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 23,500 shares during the last quarter. Institutional investors and hedge funds own 72.19% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.